Acella Recalls Two Lots of NP Thyroid

September 17, 2020 – Acella Pharmaceuticals has voluntarily recalled one lot of 15mg and one lot of 120mg NP Thyroid®, Thyroid Tablets, USP (levothyroxine and liothyronine) due to subpotency. The affected products may have as low as 87% of the labeled amount of levothyroxine.

NP Thyroid is indicated to treat hypothyroidism, which is a condition that occurs when the thyroid gland does not produce sufficient levels of thyroid hormones. Taking subpotent NP Thyroid may lead to symptoms of hypothyroidism, including fatigue, increased sensitivity to cold, slow heart rate, depression, swollen thyroid gland, weight gain, and difficulty losing weight. There is a risk of serious harm to the elderly, newborns, pregnant women, and patients who have underlying cardiac disease. As of the date of the recall, Acella has received four reports of adverse events that may be related to the affected products.

Consumers can direct questions regarding the recall to Acella by phone at 1-888-280-2044 or by email at recall@acellapharma.com. Patients should contact their healthcare provider if they have experienced any issues that may be related to use of the recalled NP Thyroid. Adverse events can also be reported to the U.S. FDA’s MedWatch program.

Additional recall details, including affected lot numbers, are available on the FDA’s website.

There is no member impact through Benecard Central Fill.